Ten billion market competition chaos war original research drugs or the biggest crisis.

Author. Eva biosimilars, also known as "biosimilars", refer to therapeutic biologics, including monotodrines, recombinant proteins, blood products, etc., that are similar in quality, safety and efficacy to approved reference drugs.
Global biosimilars reached $1.7 billion in 2014, reached $7.2 billion in 2018 and are expected to reach $164.4 billion in 2030, according to Frost Sullivan.
international and domestic, heavy original research by the "containment" in recent times, the FDA approved the 6th adamu monoantithetic biological analogue, the domestic will also usher in the first querbead monotomazumab biological similar drugs, along with the expiration of the patent of large varieties of biological agents, domestic, foreign pharmaceutical companies have accelerated action to divide the market.
's 6th "Adamu monoab" biosimilar sauer approved from 2012, Abbvie's Ahuamu monoab (Humira, Shumel) for the seventh consecutive year in the world's single drug sales of the top chair, well-deserved "drug" Wang" has been approved for the treatment of a variety of autoimmune diseases, including rheumatoid arthritis, juvenile isoarthritis, psoriasis arthritis, aggressive spinabitis, adult Crohn's disease, ulcerative colitis, plaque-type psoriasis.
, the FDA recently approved the launch of the Adalimu mono-blysa biosimilar drug Hulio (adalimumab-fkjp), developed by Mylan and Concord Kirin.
up to now, the U.S. FDA approved a total of 6 Adamu monoanti-biosimilar drugs, as follows: data sources: Pharmaceutical intelligence U.S. listed drug database in the domestic market, there are also 2 Adamu monoanti-biosimilar drugs have been approved, the following table: data source: Pharmaceutical Zhi China listed drug database, in addition, the layout of Adamu monoantiapizumadra biological drugs there are many, among them, Zhengda Qing, Junshi, Fuhonghan, 4 The soon-to-be-approved Herceptin,Herceptin is one of Roche's "troika" and has long occupied the list of top10 drug sales.
at present, Fuhong Hanququtodzumab biosimilar drug in the domestic listing application review status has been changed to "in approval", is expected to be approved for listing this month, is expected to become the first approved qutodzumab biosimilar drug.
in addition, in June 2020, Fuhong Hanxuan's tobead monotomatox biosimilars have been approved for sale in the European Union, available in all EU member states as well as in the European Economic Area countries of Norway, Iceland and Liechtenstein, and the product has been shipped.
so far, the FDA has approved five of its biosimilars: Pfizer's Trazimera, Mylan's Ogivi, Samsung's Ontruzant, Amgen/Algen's KANJINTI and Celltrion's Herzuma, which generated global sales of nearly CHF 6 billion in 2019, down 13.5 percent from a year earlier.
in addition, drug intelligence data query, there are currently 10 domestic enterprises in research, of which, Zhengda Qing and Hualan genetic engineering has entered Phase III clinical.
other heavy-duty original research crisis to small push big, you can see that the current year-round male best-selling list of large varieties of biological-similar drugs are favored.
related statistics show that there are about 180 domestic biosimilar drugs, nearly 400 drugs, in the research of biologically similar drugs are mainly CD20, EFGR, VEGF, TNF, RANKL and HER2.
in addition to Adamu monoid and qualmzumab, also includes belavbead monoidat, litoxision, Inasip, Inaxiu, Inoximono, ground sepsin, non-grestin, Pefistin, rayjuon monototag, insulin glargine, omazumab and other nearly 50 original drugs.
in the next few years, with more and more biosimilar drugs on the market, heavy original research and development drug market share will be divided, with the impact of health insurance, collection and other policies, its price, sales will continue to be affected, and biological similar drugs research and development costs slightly lower, decided that it has a more price advantage.
price war opened recently, Shaanxi Province Public Resources Trading Center issued "on the newly approved drug-related information publicity", which Cinda bio-bay-bead singofa injection, the hanging net price of 1188 yuan / bottle (4ml: 100mg).
, two biosimilars are approved for sale in China, of which The Bevala-Zhusing single injection (Anda) of Qilu was approved for listing on December 6, 2019, and Cinda's Bevala Zuma (Anvitin) was approved for listing on June 19, 2020.
Cinda Bio-Beval-Zhumono tabo price simply low 2017 National Health Insurance Negotiations made the price of Beval-Zhu monoto-ret significantly reduced, from 5210 yuan per bottle (4ml: 100mg) to 1998 yuan.
cut prices again (prices have not yet been announced) after 2019 health-care renewal talks.
before, Qilube valuing single resistance in Shandong hanging net, hanging net price of 1266 yuan / bottle (4ml: 100mg), and then reduced to 1198 yuan.
the price of this Cinda's Beval Zhu single anti-hang net is 1188 yuan / bottle (4ml: 100mg), further a new low.
next, drug prices may fall below a thousand yuan due to centralized procurement policies.
in accordance with the 2019 National Health Insurance Regulations: During the validity period, if a generic drug (generic) is listed, the health insurance department will adjust the payment standard for the drug according to the price level of the generic drug, and may also include the generic name in the scope of centralized procurement.
the current situation has been "2 -1", the price is expected to further reduce.
other biological similar drugs reduce prices Adamu monotag, the original study Ofmerajoic medical insurance payment standard 1290 yuan / branch; Haizheng 1150 yuan / branch; Hundred Aotai 1150 yuan / branch; Qutozhu monostatagain, the original research Herceptin domestic bid of 7270 yuan / 440mg, Quhong Hanqutuda single anti-biological similar drugs if successfully reduced, the price is expected to be further reduced.
with the strong support of national policies for biologically similar drugs, health insurance collection and other policies on drug price control, the original research drug will bid farewell to high prices;
the current response strategy used by the original research, in the case of AbbVie's "drug king" Xiu Merlot, although currently in the United States has been approved six, but AbbVie has previously reached a settlement agreement with nine pharmaceutical companies, according to the agreement, these pharmaceutical companies in 2023 at different points in the market.
under a licensing agreement with AbbVie, Mylan was allowed to bring Hulio to the U.S. market in July 2023.
second, is the industry's well-known operations, such as: indications expansion, combination therapy, drug system improvements and other extended life cycle of drugs.
final, commercial cooperation, such as: 2019 Samsung Bioepis and Sansheng Pharmaceuticals in China to carry out a number of biosimilar drugs in the research product clinical development and commercialization, and in Europe to launch the Adamu monosaranti-like drugs, take the joint development path.
.